NEUTRA Business Summary

Neutra Corp. (NTRR) operates primarily as a clinical research Site Management Organization (SMO) through its wholly owned subsidiary, Neutra Life Sciences. The company generates revenue through service fees and performance-based milestones by managing a network of clinical trial sites that conduct industry-sponsored research for pharmaceutical sponsors and Contract Research Organizations (CROs). Its business segments are bifurcated into its core Life Sciences division, which focuses on therapeutic areas such as oncology, pediatrics, and family medicine, and a legacy Wellness portfolio consisting of hemp-derived nutraceuticals and CBD products. As of early 2026, the company has successfully pivoted to a high-growth SMO model, projecting a 1,000% year-over-year revenue increase driven by its expansion into global clinical trial opportunities. Direct competitors include Altamira Therapeutics, Hepion Pharmaceuticals, and ProPhase Labs; Neutra Corp. distinguishes itself as a micro-cap, patient-centric specialist within the fragmented SMO market, leveraging strategic partnerships to bridge the gap between innovative medical research and community-based healthcare providers. Originally founded in 2011 by Sarah Keck, the company is currently led by Sydney Jim, who serves as President, Chief Executive Officer, Secretary, and Treasurer. Jim has overseen the firm’s strategic transformation from a nutraceutical developer into a clinical research powerhouse, emphasizing operational readiness and regulatory compliance. The leadership team is supported by a Board of Directors that includes Daniel Chen, Gilbert Fung, Cole Munger, and Amar Raval, who provide expertise in finance, legal affairs, and healthcare operations. A notable institutional milestone for the team includes being selected as an Emerging Site Partner by Parexel, a global CRO leader, which provides the company with specialized operational mentorship and enhanced access to high-impact global clinical studies.